Repligen Corp (RGEN)
Industry Medical Instruments & Supplies
This stock can be held in an Investment ISA and an Investment Account
Sell
$110.00
Buy
$128.23
$0.50 (+0.42%)
Prices updated at 01 Apr 2026, 09:27 EDT
| Prices minimum 15 mins delay
Prices in USD
Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Medical Instruments & Supplies
Chairman
Dr. Martin D. Madaus,PhD
CEO
Mr. Olivier Loeillot
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
2,000
Head office
41 Seyon Street
Waltham
United States
02453
Key personnel
Owner name | Salary |
|---|---|
Dr. Martin D. Madaus,PhD Chairman of the Board | 0.08m |
Mr. Glenn P. Muir Independent Director | 0.10m |
Ms. Karen A. Dawes, M.A. Lead Independent Director | 0.16m |
Mr. Nicolas M. Barthelemy Independent Director | 0.09m |
Ms. Carrie Eglinton Manner Independent Director | 0.07m |
Mr. Jason K. Garland Chief Financial Officer | 0.55m |
Dr. Rohin Mhatre, PhD Independent Director | 0.07m |
Dr. Konstantin Konstantinov, PhD Independent Director | 0.07m |
Ms. Violetta A. Hughes Chief Accounting Officer | - |
Mr. Olivier Loeillot Director, President and Chief Executive Officer | 0.65m |
Ms. Margaret A. Pax Independent Director | 0.05m |
Mr. Ralf Kuriyel, PhD Senior Vice President, Research and Development | 0.40m |
Mr. James R. Bylund Chief Operating Officer | 0.47m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| BlackRock Inc | 6,139,730 |
| Vanguard Group Inc | 4,993,945 |
| T. Rowe Price Associates, Inc. | 3,507,378 |
| BlackRock Fund Advisors | 3,212,301 |
| FMR Inc | 2,867,846 |
Director dealings
Date | Action |
|---|---|
| 31 Dec 2025 | - |
| 31 Dec 2025 | - |
| 17 Dec 2025 | - |
| 16 Dec 2025 | - |
| 16 Dec 2025 | - |
| 04 Dec 2025 | - |
| 25 Nov 2025 | - |
| 18 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 13 Nov 2025 | - |
| 12 Nov 2025 | - |
| 12 Nov 2025 | - |
| 12 Nov 2025 | - |
Please note that past performance is not a reliable indicator of future returns.